CN101365690A - 作为电压门控离子通道调控剂的联苯衍生物 - Google Patents

作为电压门控离子通道调控剂的联苯衍生物 Download PDF

Info

Publication number
CN101365690A
CN101365690A CNA2006800448581A CN200680044858A CN101365690A CN 101365690 A CN101365690 A CN 101365690A CN A2006800448581 A CNA2006800448581 A CN A2006800448581A CN 200680044858 A CN200680044858 A CN 200680044858A CN 101365690 A CN101365690 A CN 101365690A
Authority
CN
China
Prior art keywords
group
compound
optionally
independently
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800448581A
Other languages
English (en)
Chinese (zh)
Inventor
E·马丁波罗
D·莱斯滕
T·纽伯特
A·S·卡瓦特卡尔
N·齐默曼
A·特明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN101365690A publication Critical patent/CN101365690A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
CNA2006800448581A 2005-10-12 2006-10-12 作为电压门控离子通道调控剂的联苯衍生物 Pending CN101365690A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72568605P 2005-10-12 2005-10-12
US60/725,686 2005-10-12

Publications (1)

Publication Number Publication Date
CN101365690A true CN101365690A (zh) 2009-02-11

Family

ID=37836784

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800448581A Pending CN101365690A (zh) 2005-10-12 2006-10-12 作为电压门控离子通道调控剂的联苯衍生物

Country Status (15)

Country Link
US (2) US7683083B2 (enExample)
EP (1) EP1934191B1 (enExample)
JP (1) JP2009511599A (enExample)
KR (1) KR20080059292A (enExample)
CN (1) CN101365690A (enExample)
AT (1) ATE551333T1 (enExample)
AU (1) AU2006304283B2 (enExample)
CA (1) CA2624831A1 (enExample)
ES (1) ES2383090T3 (enExample)
IL (1) IL190632A0 (enExample)
NO (1) NO20082165L (enExample)
NZ (1) NZ567570A (enExample)
RU (1) RU2008118350A (enExample)
WO (1) WO2007047474A2 (enExample)
ZA (1) ZA200803704B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
JP2008540539A (ja) 2005-05-10 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャンネルの調節因子としての二環系誘導体
CN101218226A (zh) * 2005-05-16 2008-07-09 沃泰克斯药物股份有限公司 作为离子通道调控剂的二环衍生物
RU2008113836A (ru) * 2005-09-09 2009-10-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов
CA2624831A1 (en) * 2005-10-12 2007-04-26 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels
WO2007050522A1 (en) * 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
CA2633653A1 (en) * 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
US8193194B2 (en) 2007-05-25 2012-06-05 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
ES2377172T3 (es) * 2007-11-13 2012-03-23 Vertex Pharmaceuticals Incorporated Derivados heterocíclicos como moduladores de canales iónicos
RU2010123781A (ru) 2007-11-13 2011-12-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли
CN101978787A (zh) * 2008-04-30 2011-02-16 夏普株式会社 照明装置和显示装置
KR20110025855A (ko) * 2008-07-01 2011-03-11 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 헤테로사이클릭 유도체
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
KR102295748B1 (ko) 2013-01-31 2021-09-01 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 피리돈 아미드
US20200270237A1 (en) * 2017-10-19 2020-08-27 Esteve Pharmaceuticals, S.A. New alkoxyamino compounds for treating pain and pain related conditions
US11993581B2 (en) 2018-07-09 2024-05-28 Lieber Institue, Inc Pyridazine compounds for inhibiting Nav1.8
JP2021530478A (ja) 2018-07-09 2021-11-11 リーバー インスティチュート インコーポレイテッドLieber Institute, Inc. ＮａＶ１．８を阻害するためのピリジンカルボキシアミド化合物
WO2020163236A1 (en) * 2019-02-04 2020-08-13 The General Hospital Corporation Treating long qt syndrome
PE20250155A1 (es) 2021-06-14 2025-01-22 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2002223492A1 (en) * 2000-11-14 2002-05-27 Neurosearch A/S Use of malaria parasite anion channel blockers for treating malaria
AU2002353717B2 (en) * 2001-11-22 2006-08-03 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CN1633428A (zh) * 2001-11-22 2005-06-29 比奥维特罗姆股份公司 11－β－羟基类固醇脱氢酶1型抑制剂
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR20060073930A (ko) * 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
AU2004305321A1 (en) * 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
WO2006089871A2 (en) * 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
CA2624831A1 (en) * 2005-10-12 2007-04-26 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels

Also Published As

Publication number Publication date
NZ567570A (en) 2011-02-25
ATE551333T1 (de) 2012-04-15
RU2008118350A (ru) 2009-11-20
AU2006304283A1 (en) 2007-04-26
WO2007047474A2 (en) 2007-04-26
US20080113990A1 (en) 2008-05-15
US8236833B2 (en) 2012-08-07
CA2624831A1 (en) 2007-04-26
US20100130548A1 (en) 2010-05-27
ES2383090T3 (es) 2012-06-18
WO2007047474A3 (en) 2007-07-05
AU2006304283B2 (en) 2012-01-19
KR20080059292A (ko) 2008-06-26
IL190632A0 (en) 2008-11-03
US7683083B2 (en) 2010-03-23
JP2009511599A (ja) 2009-03-19
NO20082165L (no) 2008-07-09
ZA200803704B (en) 2009-09-30
EP1934191A2 (en) 2008-06-25
EP1934191B1 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
CN101238109B (zh) 作为离子通道调节剂的茚满衍生物
CN101365690A (zh) 作为电压门控离子通道调控剂的联苯衍生物
JP4808156B2 (ja) 電位依存型イオンチャネルの阻害剤としての縮合ピリミジン化合物
CN101218235A (zh) 作为离子通道调控剂的二环衍生物
ES2338553T3 (es) Quinazolinas utiles como moduladores de canales ionicos.
CN101331115A (zh) 调控离子通道的衍生物
EP2327701A1 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
CN101466665A (zh) 适用作电压-门控钠通道抑制剂的组合物
CN101365686A (zh) 作为离子通道调节剂的杂环衍生物
JP2009539988A (ja) イオンチャネルの調節因子として有用なチエノピリミジン
JP2010539244A (ja) イオンチャネルのモジュレーターとしてのピリジルスルホンアミド
JP2008519034A (ja) イオンチャネル調節剤としてのピリミジン誘導体および使用方法
US20100249100A1 (en) Quinazolines useful as modulators of ion channels
JP2012149084A (ja) イオンチャネルのモジュレーターとして有用なキノリン誘導体
CN101643458A (zh) 在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物
KR20080044910A (ko) 전압 개폐 이온 채널 조절인자로서의 바이사이클릭 유도체
JP2008540665A (ja) イオンチャネルのモジュレーターとして有用なビアリール
HK1088314B (en) Quinazolines useful as modulators of ion channels
AU2011250764A1 (en) Condensed Pyrimidine Compounds As Inhibitors Of Voltage-Gated Ion Channels
HK1119433B (en) Indane derivatives as modulators of ion channels

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1125365

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090211

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1125365

Country of ref document: HK